Invesaro

Stocks Comparison

LifeMD vs Oncology Institute: revenue, profit, margins and growth compared

LifeMD brought in $194.1M of revenue in fiscal 2025, Oncology Institute $502.7M in fiscal 2025. Revenue changed by +25.3% at LifeMD and +27.8% at Oncology Institute on the year before, so Oncology Institute grew faster. LifeMD kept 7.4% of its revenue as net profit, Oncology Institute -12.1%. Free cash flow was $6.4M at LifeMD and -$27.8M at Oncology Institute.

Side by side, latest fiscal year

LFMDTOI
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$194.1M$502.7M
Revenue growth+25.3%+27.8%
Net income$14.4M-$60.6M
Net margin7.4%-12.1%
Free cash flow$6.4M-$27.8M
Free cash flow margin3.3%-5.5%
Earnings per share (diluted)$0.25-$0.54
Cash$36.8M$33.6M
Debtn/a$77.4M
Price to earnings11.7n/a
Market value$141.2M$522.8M
Dividend yieldn/an/a
Rank by revenue in sector#272 of 742 · Health care#204 of 742 · Health care

Over the years

Revenue
LFMD FY2018: $8.3MLFMD FY2019: $12.5MLFMD FY2020: $37.3MLFMD FY2021: $92.9MLFMD FY2022: $119MLFMD FY2023: $152.5MLFMD FY2024: $154.8MLFMD FY2025: $194.1MTOI FY2020: $187.5MTOI FY2021: $203MTOI FY2022: $252.5MTOI FY2023: $324.2MTOI FY2024: $393.4MTOI FY2025: $502.7MFY18FY19FY20FY21FY22FY23FY24FY25
LFMD $194.1MTOI $502.7M
Net income
LFMD FY2018: -$1.2MLFMD FY2019: -$3.1MLFMD FY2020: -$58.6MLFMD FY2021: -$60.9MLFMD FY2022: -$45.5MLFMD FY2023: -$20.6MLFMD FY2024: -$21.4MLFMD FY2025: $14.4MTOI FY2020: -$14.3MTOI FY2021: -$10.9MTOI FY2022: $152KTOI FY2023: -$83.1MTOI FY2024: -$64.7MTOI FY2025: -$60.6MFY18FY19FY20FY21FY22FY23FY24FY25
LFMD $14.4MTOI -$60.6M
Net margin
LFMD FY2018: -14.9%LFMD FY2019: -25.2%LFMD FY2020: -157.3%LFMD FY2021: -65.6%LFMD FY2022: -38.3%LFMD FY2023: -13.5%LFMD FY2024: -13.8%LFMD FY2025: 7.4%TOI FY2020: -7.6%TOI FY2021: -5.4%TOI FY2022: 0.1%TOI FY2023: -25.6%TOI FY2024: -16.4%TOI FY2025: -12.1%FY18FY19FY20FY21FY22FY23FY24FY25
LFMD 7.4%TOI -12.1%
Revenue growth
LFMD FY2019: +49.8%LFMD FY2020: +199.1%LFMD FY2021: +149.0%LFMD FY2022: +28.2%LFMD FY2023: +28.2%LFMD FY2024: +1.5%LFMD FY2025: +25.3%TOI FY2021: +8.3%TOI FY2022: +24.4%TOI FY2023: +28.4%TOI FY2024: +21.3%TOI FY2025: +27.8%FY19FY20FY21FY22FY23FY24FY25
LFMD +25.3%TOI +27.8%
Free cash flow
LFMD FY2021: -$33.3MLFMD FY2022: -$23.3MLFMD FY2023: $8.6MLFMD FY2024: $16MLFMD FY2025: $6.4MTOI FY2020: -$686KTOI FY2021: -$35.5MTOI FY2022: -$67.3MTOI FY2023: -$40.9MTOI FY2024: -$30.3MTOI FY2025: -$27.8MFY20FY21FY22FY23FY24FY25
LFMD $6.4MTOI -$27.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about LifeMD and Oncology Institute

Which is bigger by revenue, LifeMD or Oncology Institute?

Oncology Institute is bigger by revenue: $502.7M in fiscal 2025, against $194.1M for LifeMD in fiscal 2025.

Which keeps more of its revenue as profit, LifeMD or Oncology Institute?

LifeMD had a net margin of 7.4% in fiscal 2025; Oncology Institute had -12.1% in fiscal 2025.

Which grew revenue faster, LifeMD or Oncology Institute?

In their latest fiscal years revenue changed by +25.3% at LifeMD and +27.8% at Oncology Institute.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies